278 related articles for article (PubMed ID: 32437908)
1. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
2. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
3. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
4. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
5. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
6. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
Riedel SS; Haladyna JN; Bezzant M; Stevens B; Pollyea DA; Sinha AU; Armstrong SA; Wei Q; Pollock RM; Daigle SR; Jordan CT; Ernst P; Neff T; Bernt KM
J Clin Invest; 2016 Apr; 126(4):1438-50. PubMed ID: 26927674
[TBL] [Abstract][Full Text] [Related]
7. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
8. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
9. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
10. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
11. The role of DOT1L in the maintenance of leukemia gene expression.
Wang X; Chen CW; Armstrong SA
Curr Opin Genet Dev; 2016 Feb; 36():68-72. PubMed ID: 27151433
[TBL] [Abstract][Full Text] [Related]
12. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
[TBL] [Abstract][Full Text] [Related]
13. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia.
Al-Kershi S; Bhayadia R; Ng M; Verboon L; Emmrich S; Gack L; Schwarzer A; Strowig T; Heckl D; Klusmann JH
Blood Adv; 2019 Dec; 3(24):4252-4263. PubMed ID: 31867596
[TBL] [Abstract][Full Text] [Related]
14. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
Richter WF; Shah RN; Ruthenburg AJ
Elife; 2021 Jul; 10():. PubMed ID: 34263728
[TBL] [Abstract][Full Text] [Related]
15. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
[TBL] [Abstract][Full Text] [Related]
16. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
17. DOT1L inhibitors block abnormal self-renewal induced by cohesin loss.
Heimbruch KE; Fisher JB; Stelloh CT; Phillips E; Reimer MH; Wargolet AJ; Meyer AE; Pulakanti K; Viny AD; Loppnow JJ; Levine RL; Pulikkan JA; Zhu N; Rao S
Sci Rep; 2021 Mar; 11(1):7288. PubMed ID: 33790356
[TBL] [Abstract][Full Text] [Related]
18. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Nguyen AT; Taranova O; He J; Zhang Y
Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
[TBL] [Abstract][Full Text] [Related]
19. Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.
Kingsley MC; Xie HM; Chen BR; Riedel SS; Pastuer T; Bollig MK; Shank T; Libbrecht C; Stabler SP; Deshpande AJ; Intlekofer AM; Bernt KM
Blood Adv; 2020 Jul; 4(13):3109-3122. PubMed ID: 32634241
[TBL] [Abstract][Full Text] [Related]
20. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]